The treatment of triple-negative breast cancer poses significant challenges due to the lack of classification antigens on the surface of cancer cells, which renders this subtype resistant to hormone therapy and targeted HER2 therapies [27]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.